Atara Biotherapeutics (ATRA) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA), Moderna (MRNA) and Madrigal Pharmaceuticals (MDGL)
Atara Biotherapeutics (ATRA) Gets a Hold From H.C. Wainwright
Atara Biotherapeutics Analyst Ratings
Goldman Sachs Sticks to Its Sell Rating for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Analyst Ratings
Mizuho Securities Downgrades Atara Biotherapeutics to Neutral From Buy, Slashes Price Target to $1 From $31
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Atara Biotherapeutics (ATRA) and Tempest Therapeutics (TPST)
H.C. Wainwright Downgrades Atara Biotherapeutics (ATRA) to a Hold
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vir Biotechnology (VIR) and Atara Biotherapeutics (ATRA)
HC Wainwright & Co. Reiterates Buy on Atara Biotherapeutics, Maintains $28 Price Target
Atara Biotherapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO), Harmony Biosciences Holdings (HRMY) and Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Analyst Ratings
EF Hutton Reiterates Buy on Atara Biotherapeutics, Maintains $25 Price Target
Atara Biotherapeutics Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Atara Biotherapeutics (ATRA)
Atara Biotherapeutics (ATRA) Receives a Buy From Mizuho Securities
Mizuho Securities Remains a Buy on Atara Biotherapeutics (ATRA)
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Akebia Therapeutics (AKBA)
No Data